logo
Plus   Neg
Share
Email

Medtronic To Launch Study For Implantable Tibial Neuromodulation Therapy In Bladder Incontinence

Medtronic plc (MDT) announced FDA approval to proceed with an investigational device exemption trial to evaluate its implantable tibial neuromodulation device — a therapy designed to provide relief from symptoms of bladder incontinence.

The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable tibial neuromodulation device in subjects with bladder incontinence. Medtronic said twenty patients from eight sites in the U.S. will receive a device and will be followed for 12 months. Enrollment is anticipated to begin in May 2021.

For comments and feedback contact: editorial@rttnews.com

Follow RTT